Next-generation Superkines

Medicenna has an exclusive license to a library of revolutionary cytokines, called Superkines, from Stanford University. These cytokines include IL-2, IL-4 and IL-13, which have been engineered to bind to different receptor subtypes with variable specificity and affinity, enabling fine tuning of signalling pathways, cellular responses and cell fate. Additionally, by fusing the Superkines to protein scaffolds, Medicenna is able to generate long-acting Superkines (like MDNA11) with superior PK properties or Empowered Superkines (like MDNA55) that can carry potent warheads with precision to the target.

In addition to the above, there are many different opportunities to further create value with our Superkines, as shown in the graphic.